Market view
300+ marketed package NDCs · 18 active manufacturers
Most dispensed: 2.5 mg/.5mL · Injection, Solution · #4 syringes/carton / .5 ml in 1 syringe · 5 mg/.5mL · Injection, Solution · #4 syringes/carton / .5 ml in 1 syringe · 10 mg/.5mL · Injection, Solution · #4 syringes/carton / .5 ml in 1 syringe · 7.5 mg/.5mL · Injection, Solution · #4 syringes/carton / .5 ml in 1 syringe
18 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $525.78 per mL over the past year. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $525.78 · middle half $281.65–$538.48 · full range $200.70–$538.64 · 18 products · 40 companies
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Every detected change for tirzepatide, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Other molecules FDA puts in GLP-1 Receptor Agonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.